Assay Detects Antibodies Associated with Heparin-Induced Thrombocytopenia

A fully automated panel for the detection of heparin-induced thrombocytopenia (HIT) has been released. The assays provide enhanced detection of HIT antibodies in specialty and hospital hemostasis laboratories.

The panel includes HemosIL AcuStar HIT-IgG (PF4-H) and HemosIL AcuStar HIT-Ab (PF4-H) assays. These are on-demand, fully automated, chemiluminescent reagents on a hemostasis testing system for the detection of antibodies associated with HIT.

The ready-to-use, cartridge-based assays offer results in approximately 30 minutes, on-demand, 24/7. The precalibrated reagent cartridges offer significant time- and cost-efficiencies.

HIT is a severe immunologic adverse reaction to heparin, paradoxically resulting in venous and/or arterial thrombosis. It is one of the most common of all adverse drug effects, due to the large number of patients receiving heparin therapy.

If HIT is untreated, the risk of dangerous conditions developing such as stroke, pulmonary embolism, and even death increases significantly.

The assays are products of Instrumentation Laboratory (Bedford, MA, USA). The new HemosIL AcuStar HIT Assay Panel assay has been released as a European CE in vitro diagnostic (IVD) Mark product. The assays are not currently 510(k) cleared.

Related Links:
Instrumentation Laboratory